A detailed history of Jpmorgan Chase & CO transactions in Nektar Therapeutics stock. As of the latest transaction made, Jpmorgan Chase & CO holds 913,300 shares of NKTR stock, worth $831,103. This represents 0.0% of its overall portfolio holdings.

Number of Shares
913,300
Previous 307,243 197.26%
Holding current value
$831,103
Previous $380,000 212.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.11 - $1.48 $672,723 - $896,964
606,057 Added 197.26%
913,300 $1.19 Million
Q2 2024

Aug 12, 2024

BUY
$0.9 - $1.83 $275,950 - $561,099
306,612 Added 48591.44%
307,243 $380,000
Q4 2023

Feb 12, 2024

SELL
$0.42 - $0.57 $15,166 - $20,582
-36,110 Reduced 98.28%
631 $0
Q3 2023

Nov 14, 2023

BUY
$0.51 - $1.05 $15,106 - $31,102
29,621 Added 416.03%
36,741 $22,000
Q2 2023

Aug 11, 2023

SELL
$0.53 - $1.03 $119,443 - $232,126
-225,366 Reduced 96.94%
7,120 $4,000
Q1 2023

May 18, 2023

BUY
$0.64 - $3.15 $147,503 - $725,993
230,474 Added 11454.97%
232,486 $162,000
Q1 2023

May 11, 2023

SELL
$0.64 - $3.15 $120,954 - $595,321
-188,991 Reduced 98.95%
2,012 $1,000
Q4 2022

Feb 13, 2023

SELL
$2.03 - $4.28 $80,422 - $169,560
-39,617 Reduced 17.18%
191,003 $433,000
Q3 2022

Nov 14, 2022

SELL
$3.04 - $5.14 $1.33 Million - $2.24 Million
-435,950 Reduced 65.4%
230,620 $738,000
Q2 2022

Aug 11, 2022

BUY
$3.17 - $6.17 $1.53 Million - $2.99 Million
483,932 Added 264.97%
666,570 $2.53 Million
Q1 2022

May 11, 2022

BUY
$4.16 - $13.72 $472,014 - $1.56 Million
113,465 Added 164.03%
182,638 $985,000
Q4 2021

Feb 10, 2022

SELL
$10.83 - $18.41 $1.78 Million - $3.02 Million
-164,122 Reduced 70.35%
69,173 $935,000
Q3 2021

Nov 12, 2021

BUY
$13.07 - $18.84 $3.05 Million - $4.4 Million
233,295 New
233,295 $4.19 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.